Cargando…

TRLS-03. PHASE II TRIAL OF GDC-0084 IN COMBINATION WITH TRASTUZUMAB FOR PATIENTS WITH HER2-POSITIVE BREAST CANCER BRAIN METASTASES (BCBM)

BACKGROUND: The PI3K/Akt/mTOR is an important pathway in BCBM. Mutations in PIK3CA or PTEN loss are associated with trastuzumab resistance. Inhibition of PI3K and mTOR led to durable responses in 3 of 5 patient-derived xenografts (PDX) models of BCBM. GDC-0084 is a potent, brain-penetrant inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leone, Jose Pablo, Trippa, Lorenzo, Milisits, Lindsey, Andrews, Chelsea, Ligibel, Jennifer, Parsons, Heather, Bi, Wenya, Zhao, Jean, Winer, Eric, Lin, Nancy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213424/ http://dx.doi.org/10.1093/noajnl/vdz014.036

Ejemplares similares

Discovery of Clinical Development Candidate GDC-0084, a Brain Penetrant Inhibitor of PI3K and mTOR
por: Heffron, Timothy P., et al.
Publicado: (2016)

Identification of plicamycin, TG02, panobinostat, lestaurtinib, and GDC-0084 as promising compounds for the treatment of central nervous system infections caused by the free-living amebae Naegleria, Acanthamoeba and Balamuthia
por: Kangussu-Marcolino, Monica M., et al.
Publicado: (2019)

EHMTI-0084. Resting state functional connectivity abnormalities in pediatric patients with migraine
por: Messina, R, et al.
Publicado: (2014)

A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer
por: Schöffski, Patrick, et al.
Publicado: (2018)

Targeting HER2 in breast cancer: beyond trastuzumab
por: Winer, EP
Publicado: (2011)

TRLS-03. Intracranial activity of tepotinib in patients with MET exon 14 (METex14) skipping NSCLC enrolled in VISION
por: Bestvina, Christine M, et al.
Publicado: (2021)

GDC respond to crisis
Publicado: (2020)

Mentoring, performance and the GDC
por: Saw, Mabel, et al.
Publicado: (2021)

TRLS-03. IBRUTINIB DISRUPTS BLOOD-TUMOR BARRIER INTEGRITY TO ENHANCE CNS DRUG DELIVERY AND RODENT GLIOMA MODEL SURVIVAL
por: Lim, Sanghee, et al.
Publicado: (2023)

TRLS-04. A Nomogram for Predicting Survival in Patients with Brain Metastases
por: Wang, Zhenning, et al.
Publicado: (2021)

GDC announces new chair
Publicado: (2021)

Circular RNA circBCBM1 promotes breast cancer brain metastasis by modulating miR-125a/BRD4 axis
por: Fu, Bo, et al.
Publicado: (2021)

TRLS-12. INTRAVENTRICULAR B7-H3 CAR T CELLS FOR DIFFUSE INTRINSIC PONTINE GLIOMA: INTERIM ANALYSIS OF BRAINCHILD-03 ARM C
por: Vitanza, Nicholas, et al.
Publicado: (2023)

Novel approaches to target HER2-positive breast cancer: trastuzumab emtansine
por: Recondo, Gonzalo, et al.
Publicado: (2016)

GDC 2: Compression of large collections of genomes
por: Deorowicz, Sebastian, et al.
Publicado: (2015)

GDC publishes 2019 fitness to practise statistics
Publicado: (2020)

GDC statement on complaints during the pandemic welcomed
Publicado: (2022)

GDC calls for DCPs to check CPD records
Publicado: (2022)

GDC calls for DCPs to check CPD records
Publicado: (2022)

The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 −) advanced/metastatic breast cancer
por: Bardia, Aditya, et al.
Publicado: (2022)

GDC and CQC issue statement on life-support training
Publicado: (2020)

TRLS-16. RAPID GENERATION OF EPENDYMOMA MOUSE MODELS FOR PRE-CLINICAL STUDIES
por: Ippagunta, Siri, et al.
Publicado: (2023)

Effect of Trastuzumab–HER2 Complex Formation on Stress-Induced Modifications in the CDRs of Trastuzumab
por: Spanov, Baubek, et al.
Publicado: (2022)

Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases
por: Mills, Matthew N., et al.
Publicado: (2021)

HER2+ esophageal carcinoma leptomeningeal metastases treated with intrathecal trastuzumab regimen
por: Wu, Scott A, et al.
Publicado: (2023)

GDC highlights importance of clear public safety COVID information
Publicado: (2020)

TRLS-04. PRECLINICAL VALIDATION OF A NOVEL THERAPEUTIC STRATEGY FOR CHOROID PLEXUS CARCINOMA
por: Martin, Brice, et al.
Publicado: (2023)

TRLS-14. TARGETING REPLICATIVE STRESS IN BRAIN TUMORS BY COMBINING ATR AND PARP INHIBITION
por: Sarvode, Supriya, et al.
Publicado: (2023)

TRLS-15. TARGETED THERAPY IN PEDIATRIC CNS TUMORS - A SINGLE INSTITUTION EXPERIENCE
por: Olsen, Braden, et al.
Publicado: (2023)

HER2 therapy: Molecular mechanisms of trastuzumab resistance
por: Nahta, Rita, et al.
Publicado: (2006)

Quantification of Trastuzumab–HER2 Engagement In Vitro and In Vivo
por: Rudkouskaya, Alena, et al.
Publicado: (2020)

GDC-0941 activates integrin linked kinase (ILK) expression to cause resistance to GDC-0941 in breast cancer by the tumor necrosis factor (TNF)-α signaling pathway
por: Chen, Haifeng, et al.
Publicado: (2022)

Heterogeneous distribution of trastuzumab in HER2-positive xenografts and metastases: role of the tumor microenvironment
por: Baker, Jennifer Hazel Elizabeth, et al.
Publicado: (2018)

TRLS-02. FEASIBILITY OF EVALUATING ABEMACICLIB NEUROPHARMACOKINETICS OF DIFFUSE MIDLINE GLIOMA USING INTRATUMORAL MICRODIALYSIS
por: Jackson, Sadhana, et al.
Publicado: (2023)

eDAVE – Extension of GDC data analysis, visualization, and exploration tools
por: Bińkowski, Jan, et al.
Publicado: (2023)

Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
por: Yang, Jiangping, et al.
Publicado: (2022)

TRLS-07. Intracavitary carrier-embedded Cs131 brachytherapy for recurrent brain metastases: A randomized phase II study
por: Moss, Nelson S, et al.
Publicado: (2021)

Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial
por: Lin, Nancy U., et al.
Publicado: (2020)

53. TUCATINIB VS PLACEBO ADDED TO TRASTUZUMAB AND CAPECITABINE FOR PATIENTS WITH PREVIOUSLY TREATED HER2+ METASTATIC BREAST CANCER (MBC) WITH BRAIN METASTASES (BM) (HER2CLIMB)
por: Lin, Nancy, et al.
Publicado: (2020)

Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer
por: Soo Park, Ji, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_g9eq7trod5ni350q76rjiqkslg